1. Home
  2. DC vs ESPR Comparison

DC vs ESPR Comparison

Compare DC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dakota Gold Corp.

DC

Dakota Gold Corp.

HOLD

Current Price

$5.01

Market Cap

843.8M

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.13

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DC
ESPR
Founded
2017
2008
Country
United States
United States
Employees
41
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
843.8M
731.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
DC
ESPR
Price
$5.01
$3.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$9.48
$8.75
AVG Volume (30 Days)
1.1M
9.9M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.31
52 Week Low
$3.60
$0.95
52 Week High
$7.25
$4.18

Technical Indicators

Market Signals
Indicator
DC
ESPR
Relative Strength Index (RSI) 39.10 69.52
Support Level $4.38 $3.11
Resistance Level $5.08 $3.18
Average True Range (ATR) 0.31 0.01
MACD -0.04 -0.03
Stochastic Oscillator 2.91 75.00

Price Performance

Historical Comparison
DC
ESPR

About DC Dakota Gold Corp.

Dakota Gold Corp is a gold exploration and development company focused on revitalizing the Homestake District in Lead, South Dakota. The company holds gold mineral properties surrounding the historic Homestake Mine and is advancing key projects, including the Richmond Hill Project.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: